High-density lipoprotein (HDL) is one of the five major groups of lipoproteins.[1] Lipoproteins are complex particles composed of multiple proteins which transport all fat molecules (lipids) around the body within the water outside cells. They are typically composed of 80–100 proteins per particle (organized by one, two or three ApoA). HDL particles enlarge while circulating in the blood, aggregating more fat molecules and transporting up to hundreds of fat molecules per particle.[2]

Overview

Lipoproteins are divided into five subgroups, by density/size (an inverse relationship), which also correlates with function and incidence of cardiovascular events. Unlike the larger lipoprotein particles, which deliver fat molecules to cells, HDL particles remove fat molecules from cells. The lipids carried include cholesterol, phospholipids, and triglycerides, amounts of each are variable.[3]

Increasing concentrations of HDL particles are associated with decreasing accumulation of atherosclerosis within the walls of arteries,[4] reducing the risk of sudden plaque ruptures, cardiovascular disease, stroke and other vascular diseases.[2] HDL particles are commonly referred to as "good cholesterol", because they transport fat molecules out of artery walls, reduce macrophage accumulation, and thus help prevent or even regress atherosclerosis.[5] However, recent investigations have shown that very high concentrations of HDL particles can be associated with an increased mortality risk[6] and an increased cardiovascular risk, especially in hypertensive patients.[7]

Testing

Because of the high cost of directly measuring HDL and LDL (low-density lipoprotein) protein particles, blood tests are commonly performed for the surrogate value, HDL-C, i.e. the cholesterol associated with ApoA-1/HDL particles. In healthy individuals, about 30% of blood cholesterol, along with other fats, is carried by HDL.[5] This is often contrasted with the amount of cholesterol estimated to be carried within low-density lipoprotein particles, LDL, and called LDL-C. HDL particles remove fats and cholesterol from cells, including within artery wall atheroma, and transport it back to the liver for excretion or re-utilization; thus the cholesterol carried within HDL particles (HDL-C) is sometimes called "good cholesterol" (despite being the same as cholesterol in LDL particles). Those with higher levels of HDL-C tend to have fewer problems with cardiovascular diseases, while those with low HDL-C cholesterol levels (especially less than 40 mg/dL or about 1 mmol/L) have increased rates for heart disease.[8] Higher native HDL levels are correlated with lowered risk of cardiovascular disease in healthy people.[9]

The remainder of the serum cholesterol after subtracting the HDL is the non-HDL cholesterol. The concentration of these other components, which may cause atheroma, is known as the non-HDL-C. This is now preferred to LDL-C as a secondary marker as it has been shown to be a better predictor and it is more easily calculated.[10]

Structure and function

With a size ranging from 5 to 17 nm, HDL is the smallest of the lipoprotein particles.[2] It is the densest because it contains the highest proportion of protein to lipids.[2] Its most abundant apolipoproteins are apo A-I and apo A-II. A rare genetic variant, ApoA-1 Milano, has been documented to be far more effective in both protecting against and regressing arterial disease, atherosclerosis.

The liver synthesizes these lipoproteins as complexes of apolipoproteins and phospholipid, which resemble cholesterol-free flattened spherical lipoprotein particles,[2] whose NMR structure was recently published;[11] the complexes are capable of picking up cholesterol, carried internally, from cells by interaction with the ATP-binding cassette transporter A1 (ABCA1).[12] A plasma enzyme called lecithin-cholesterol acyltransferase (LCAT) converts the free cholesterol into cholesteryl ester (a more hydrophobic form of cholesterol), which is then sequestered into the core of the lipoprotein particle, eventually causing the newly synthesized HDL to assume a spherical shape. HDL particles increase in size as they circulate through the blood and incorporate more cholesterol and phospholipid molecules from cells and other lipoproteins, such as by interaction with the ABCG1 transporter and the phospholipid transport protein (PLTP).[2]

HDL transports cholesterol mostly to the liver or steroidogenic organs such as adrenals, ovary, and testes by both direct and indirect pathways. HDL is removed by HDL receptors such as scavenger receptor BI (SR-BI), which mediate the selective uptake of cholesterol from HDL. In humans, probably the most relevant pathway is the indirect one, which is mediated by cholesteryl ester transfer protein (CETP).[2] This protein exchanges triglycerides of VLDL against cholesteryl esters of HDL. As the result, VLDLs are processed to LDL, which are removed from the circulation by the LDL receptor pathway. The triglycerides are not stable in HDL, but are degraded by hepatic lipase so that, finally, small HDL particles are left, which restart the uptake of cholesterol from cells.[2]

The cholesterol delivered to the liver is excreted into the bile and, hence, intestine either directly or indirectly after conversion into bile acids. Delivery of HDL cholesterol to adrenals, ovaries, and testes is important for the synthesis of steroid hormones.[2]

Several steps in the metabolism of HDL can participate in the transport of cholesterol from lipid-laden macrophages of atherosclerotic arteries, termed foam cells, to the liver for secretion into the bile. This pathway has been termed reverse cholesterol transport and is considered as the classical protective function of HDL toward atherosclerosis.

HDL carries many lipid and protein species, several of which have very low concentrations but are biologically very active. For example, HDL and its protein and lipid constituents help to inhibit oxidation, inflammation, activation of the endothelium, coagulation, and platelet aggregation. All these properties may contribute to the ability of HDL to protect from atherosclerosis, and it is not yet known which are the most important. In addition, a small subfraction of HDL lends protection against the protozoan parasite Trypanosoma brucei brucei. This HDL subfraction, termed trypanosome lytic factor (TLF), contains specialized proteins that, while very active, are unique to the TLF molecule.[13]

In the stress response, serum amyloid A, which is one of the acute-phase proteins and an apolipoprotein, is under the stimulation of cytokines (interleukin 1, interleukin 6), and cortisol produced in the adrenal cortex and carried to the damaged tissue incorporated into HDL particles. At the inflammation site, it attracts and activates leukocytes. In chronic inflammations, its deposition in the tissues manifests itself as amyloidosis.

It has been postulated that the concentration of large HDL particles more accurately reflects protective action, as opposed to the concentration of total HDL particles.[14] This ratio of large HDL to total HDL particles varies widely and is measured only by more sophisticated lipoprotein assays using either electrophoresis (the original method developed in the 1970s) or newer NMR spectroscopy methods (See also nuclear magnetic resonance and spectroscopy), developed in the 1990s.

Subfractions

Five subfractions of HDL have been identified. From largest (and most effective in cholesterol removal) to smallest (and least effective), the types are 2a, 2b, 3a, 3b, and 3c.[15]

Epidemiology

Men tend to have noticeably lower HDL concentrations, with smaller size and lower cholesterol content, than women. Men also have a greater incidence of atherosclerotic heart disease. Recent studies confirm the fact that HDL has a buffering role in balancing the effects of the hypercoagulable state in type 2 diabetics and decreases the high risk of cardiovascular complications in these patients. Also, the results obtained in this study revealed that there was a significant negative correlation between HDL and activated partial thromboplastin time (APTT).

Epidemiological studies have shown that high concentrations of HDL (over 60 mg/dL) have protective value against cardiovascular diseases such as ischemic stroke and myocardial infarction. Low concentrations of HDL (below 40 mg/dL for men, below 50 mg/dL for women) increase the risk for atherosclerotic diseases.

Data from the landmark Framingham Heart Study showed that, for a given level of LDL, the risk of heart disease increases 10-fold as the HDL varies from high to low. On the converse, however, for a fixed level of HDL, the risk increases 3-fold as LDL varies from low to high.[16][17]

Even people with very low LDL levels under statins treatment are exposed to increased risk if their HDL levels are not high enough.[18]

Estimating HDL via associated cholesterol

Clinical laboratories formerly measured HDL cholesterol by separating other lipoprotein fractions using either ultracentrifugation or chemical precipitation with divalent ions such as Mg2+, then coupling the products of a cholesterol oxidase reaction to an indicator reaction. The reference method still uses a combination of these techniques.[19] Most laboratories now use automated homogeneous analytical methods in which lipoproteins containing apo B are blocked using antibodies to apo B, then a colorimetric enzyme reaction measures cholesterol in the non-blocked HDL particles.[20] HPLC can also be used.[21] Subfractions (HDL-2C, HDL-3C) can be measured,[22] but clinical significance of these subfractions has not been determined.[23] The measurement of apo-A reactive capacity can be used to measure HDL cholesterol but is thought to be less accurate.

The American Heart Association, NIH and NCEP provide a set of guidelines for fasting HDL levels and risk for heart disease.[24][25][26]

Level mg/dL Level mmol/L Interpretation
<40/50 men/women <1.03 Low HDL cholesterol, heightened risk considered correlated for heart disease
40–59 1.03–1.55 Medium HDL level
>59 >1.55 High HDL level, optimal condition considered correlated against heart disease

High LDL with low HDL level is an additional risk factor for cardiovascular disease.[27]

Measuring HDL concentration and sizes

As technology has reduced costs and clinical trials have continued to demonstrate the importance of HDL, methods for directly measuring HDL concentrations and size (which indicates function) at lower costs have become more widely available and increasingly regarded as important for assessing individual risk for progressive arterial disease and treatment methods.

Electrophoresis measurements

Since the HDL particles have a net negative charge and vary by density & size, ultracentrifugation combined with electrophoresis have been utilized since before 1950 to enumerate the concentration of HDL particles and sort them by size with a specific volume of blood plasma. Larger HDL particles are carrying more cholesterol.

NMR measurements

Concentration and sizes of lipoprotein particles can be estimated using nuclear magnetic resonance fingerprinting.[28]

Optimal total and large HDL concentrations

The HDL particle concentrations are typically categorized by event rate percentiles based on the people participating and being tracked in the MESA[29] trial, a medical research study sponsored by the United States National Heart, Lung, and Blood Institute.

Total HDL particle Table
MESA Percentile Total HDL particles μmol/L Interpretation
>75% >34.9 Those with highest (Optimal) total HDL particle concentrations & lowest rates of cardiovascular disease events
50–75% 30.5–34.5 Those with moderately high total HDL particle concentrations & moderate rates of cardiovascular disease events
25–50% 26.7–30.5 Those with lower total HDL particle concentrations & Borderline-High rates of cardiovascular disease
0–25% <26.7 Those with lowest total HDL particle concentrations & Highest rates of cardiovascular disease events
Large (protective) HDL particle Table
MESA Percentile Large HDL particles μmol/L Interpretation
>75% >7.3 Those with highest (Optimal) Large HDL particle concentrations & lowest rates of cardiovascular disease events
50–75% 4.8–7.3 Those with moderately high Large HDL particle concentrations & moderate rates of cardiovascular disease events
25–50% 3.1–4.8 Those with lower Large HDL particle concentrations & Borderline-High rates of cardiovascular disease
0–25% <3.1 Those with lowest Large HDL particle concentrations & Highest rates of cardiovascular disease events

The lowest incidence of atherosclerotic events over time occurs within those with both the highest concentrations of total HDL particles (the top quarter, >75%) and the highest concentrations of large HDL particles. Multiple additional measures, including LDL particle concentrations, small LDL particle concentrations, VLDL concentrations, estimations of insulin resistance and standard cholesterol lipid measurements (for comparison of the plasma data with the estimation methods discussed above) are routinely provided in clinical testing.

Increasing HDL levels

While higher HDL levels are correlated with lower risk of cardiovascular diseases, no medication used to increase HDL has been proven to improve health.[2][30] As of 2017, numerous lifestyle changes and drugs to increase HDL levels were under study.[2]

HDL lipoprotein particles that bear apolipoprotein C3 are associated with increased, rather than decreased, risk for coronary heart disease.[31]

Diet and exercise

Certain changes in diet and exercise may have a positive impact on raising HDL levels:[32]

Most saturated fats increase HDL cholesterol to varying degrees but also raise total and LDL cholesterol.[46]

Recreational drugs

HDL levels can be increased by smoking cessation,[38] or mild to moderate alcohol intake.[47][48][49][50][51][52]

Cannabis in unadjusted analyses, past and current cannabis use was not associated with higher HDL-C levels.[53] A study performed in 4635 patients demonstrated no effect on the HDL-C levels (P=0.78) [the mean (standard error) HDL-C values in control subjects (never used), past users and current users were 53.4 (0.4), 53.9 (0.6) and 53.9 (0.7) mg/dL, respectively].[53]

Exogenous anabolic androgenic steroids, particularly 17α-alkylated anabolic steroids and others administered orally, can reduce HDL-C by 50 percent or more.[54] Other androgen receptor agonists such as selective androgen receptor modulators can also lower HDL. As there is some evidence that the HDL reduction is caused by increased reverse cholesterol transport, it is unknown if AR agonists' HDL-lowering effect is pro- or anti-atherogenic.[55]

Pharmaceutical drugs and niacin

Pharmacological therapy to increase the level of HDL cholesterol includes use of fibrates and niacin. Fibrates have not been proven to have an effect on overall deaths from all causes, despite their effects on lipids.[56]

Niacin (nicotinic acid, a form of vitamin B3) increases HDL by selectively inhibiting hepatic diacylglycerol acyltransferase 2, reducing triglyceride synthesis and VLDL secretion through a receptor HM74[57] otherwise known as niacin receptor 2 and HM74A / GPR109A,[58] niacin receptor 1.

Pharmacologic (1- to 3-gram/day) niacin doses increase HDL levels by 10–30%,[59] making it the most powerful agent to increase HDL-cholesterol.[60][61] A randomized clinical trial demonstrated that treatment with niacin can significantly reduce atherosclerosis progression and cardiovascular events.[62] Niacin products sold as "no-flush", i.e. not having side-effects such as "niacin flush", do not, however, contain free nicotinic acid and are therefore ineffective at raising HDL, while products sold as "sustained-release" may contain free nicotinic acid, but "some brands are hepatotoxic"; therefore the recommended form of niacin for raising HDL is the cheapest, immediate-release preparation.[63] Both fibrates and niacin increase artery toxic homocysteine, an effect that can be counteracted by also consuming a multivitamin with relatively high amounts of the B-vitamins, but multiple European trials of the most popular B-vitamin cocktails, trial showing 30% average reduction in homocysteine, while not showing problems have also not shown any benefit in reducing cardiovascular event rates. A 2011 extended-release niacin (Niaspan) study was halted early because patients adding niacin to their statin treatment showed no increase in heart health, but did experience an increase in the risk of stroke.[64]

In contrast, while the use of statins is effective against high levels of LDL cholesterol, most have little or no effect in raising HDL cholesterol.[60] Rosuvastatin and pitavastatin, however, have been demonstrated to significantly raise HDL levels.[65]

Lovaza has been shown to increase HDL-C.[66] However, the best evidence to date suggests it has no benefit for primary or secondary prevention of cardiovascular disease.

The PPAR modulator GW501516 has shown a positive effect on HDL-C[67] and an antiatherogenic where LDL is an issue.[68] However, research on the drug has been discontinued after it was discovered to cause rapid cancer development in several organs in rats.[69][70]

See also

References

  1. ↑ "LDL and HDL: Bad and Good Cholesterol". Centers for Disease Control and Prevention. CDC. Archived from the original on 12 September 2017. Retrieved 11 September 2017.
  2. 1 2 3 4 5 6 7 8 9 10 11 Deng S, Xu Y, Zheng L (2022). "HDL Structure". HDL Metabolism and Diseases. Advances in Experimental Medicine and Biology. Vol. 1377. pp. 1–11. doi:10.1007/978-981-19-1592-5_1. ISBN 978-981-19-1591-8. PMID 35575917.
  3. ↑ Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson WS (2015). "Structure of HDL: particle subclasses and molecular components". High Density Lipoproteins. Handbook of Experimental Pharmacology. Vol. 224. pp. 3–51. doi:10.1007/978-3-319-09665-0_1. ISBN 978-3-319-09664-3. PMID 25522985.
  4. ↑ Casula M, Colpani O, Xie S, Catapano AL, Baragetti A (July 2021). "HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role". Cells. 10 (8): 1869. doi:10.3390/cells10081869. PMC 8394469. PMID 34440638.
  5. 1 2 "HDL (Good), LDL (Bad) Cholesterol and Triglycerides". American Heart Association. 2021. Archived from the original on 28 July 2018. Retrieved 31 May 2021.
  6. ↑ Madsen CM, Varbo A, Nordestgaard BG (August 2017). "Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies". Eur Heart J. 38 (32): 2478–2486. doi:10.1093/eurheartj/ehx163. PMID 28419274.
  7. ↑ Trimarco V, Izzo R, Morisco C, Mone P, Maria Virginia M, Falco A, Pacella D, Gallo P, Lembo M, Santulli G, Trimarco B (August 2022). "High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients". Hypertension. 79 (10): 2355–2363. doi:10.1161/HYPERTENSIONAHA.122.19912. PMC 9617028. PMID 35968698.
  8. ↑ Toth PP (Feb 2005). "Cardiology patient page. The "good cholesterol": high-density lipoprotein". Circulation. 111 (5): e89–e91. doi:10.1161/01.CIR.0000154555.07002.CA. PMID 15699268. Archived from the original on 2011-05-29. Retrieved 2011-06-02.
  9. ↑ Sirtori, Cesare R. (October 2006). "HDL and the progression of atherosclerosis: new insights". European Heart Journal Supplements. Archived from the original on 2015-02-01.
  10. ↑ M.J. Sorrentino (2011), "Non-HDL-Cholesterol", Hyperlipidemia in Primary Care, Springer, pp. 86–87, ISBN 978-1-60327-502-6
  11. ↑ Bibow S; et al. (2017), "Solution structure of discoidal high-density lipoprotein particles with a shortened apolipoprotein A-I", Nature Structural & Molecular Biology, 24 (6): 187–93, doi:10.1038/nsmb.3345, PMID 28024148, S2CID 27875177
  12. ↑ Huang CX, Zhang YL (2013). "The target of regulating the ATP-binding cassette A1 protein (ABCA1): promoting ABCA1-mediated cholesterol efflux in different cells". Current Pharmaceutical Biotechnology. 14 (6): 623–31. doi:10.2174/138920101131400228. PMID 24016265.
  13. ↑ Stephens NA, Kieft R, Macleod A, Hajduk SL (Dec 2012). "Trypanosome resistance to human innate immunity: targeting Achilles' heel". Trends in Parasitology. 28 (12): 539–45. doi:10.1016/j.pt.2012.09.002. PMC 4687903. PMID 23059119.
  14. ↑ Kwiterovich PO (Dec 2000). "The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review". The American Journal of Cardiology. 86 (12A): 5L–10L. doi:10.1016/S0002-9149(00)01461-2. PMID 11374859.
  15. ↑ "HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men". Archived from the original on 2012-06-18. Retrieved 2012-06-11.
  16. ↑ Rahilly-Tierney CR, Spiro A, Vokonas P, Gaziano JM (Apr 2011). "Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study)". The American Journal of Cardiology. 107 (8): 1173–7. doi:10.1016/j.amjcard.2010.12.015. PMID 21296318.
  17. ↑ Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002). "Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)". Archives of Internal Medicine. 162 (22): 2597–604. doi:10.1001/archinte.162.22.2597. PMID 12456232.
  18. ↑ Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC (Sep 2007). "HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events". The New England Journal of Medicine. 357 (13): 1301–10. doi:10.1056/NEJMoa064278. PMID 17898099. S2CID 44794291.
  19. ↑ "National Reference System for Cholesterol – Cholesterol Reference Method Laboratory Network – HDL Cholesterol Certification Protocol for Manufacturers" (PDF). CDC. Archived (PDF) from the original on 10 November 2013. Retrieved 10 November 2013.
  20. ↑ Warnick GR, Nauck M, Rifai N (Sep 2001). "Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays". Clinical Chemistry. 47 (9): 1579–1596. doi:10.1093/clinchem/47.9.1579. PMID 11514391. Archived from the original on 2014-03-13. Retrieved 2013-11-10.
  21. ↑ Okazaki M, Sasamoto K, Muramatsu T, Hosaki S (Oct 1997). "Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC". Clinical Chemistry. 43 (10): 1885–90. doi:10.1093/clinchem/43.10.1885. PMID 9342008. Archived from the original on 2008-07-24. Retrieved 2009-10-08.
  22. ↑ Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y (May 2008). "A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay". Journal of Lipid Research. 49 (5): 1130–6. doi:10.1194/jlr.D700027-JLR200. PMID 18223297.
  23. ↑ Superko HR, Pendyala L, Williams PT, Momary KM, King SB 3rd, Garrett BC (2012). "High-density lipoprotein subclasses and their relationship to cardiovascular disease". Journal of Clinical Lipidology. 6 (6): 496–523. doi:10.1016/j.jacl.2012.03.001. PMID 23312047.
  24. ↑ "Cholesterol Levels". American Heart Association. Archived from the original on 8 February 2010. Retrieved 14 November 2009.
  25. ↑ "What Do My Cholesterol Levels Mean?" (PDF). American Heart Association. September 2007. Archived from the original (PDF) on 3 December 2008. Retrieved 14 November 2009.
  26. ↑ "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary" (PDF). National Heart, Lung, and Blood Institute (NHLBI). National Institutes of Health. May 2001. Archived (PDF) from the original on 2009-08-02. Retrieved 2009-12-03.
  27. ↑ ASHWOOD, E. R., BURTIS, C. A., & BRUNS, D. E. (2008). Tietz fundamentals of clinical chemistry. (6th ed., p. 415). St. Louis, MO: Saunders Elsevier.
  28. ↑ Jeyarajah EJ, Cromwell WC, Otvos JD (2006). "Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy". Clin. Lab. Med. 26 (4): 847–70. doi:10.1016/j.cll.2006.07.006. PMID 17110242.
  29. ↑ "mesa-nhlbi.org". Archived from the original on 2016-12-15. Retrieved 2016-12-07.
  30. ↑ Keene D, Price C, Shun-Shin MJ, Francis DP (Jul 18, 2014). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients". BMJ. 349: g4379. doi:10.1136/bmj.g4379. PMC 4103514. PMID 25038074.
  31. ↑ Sacks FM, Zheng C, Cohn JS (2011). "Complexities of plasma apolipoprotein C-III metabolism". Journal of Lipid Research. 52 (6): 1067–1070. doi:10.1194/jlr.E015701. PMC 3090227. PMID 21421846.
  32. ↑ Fogoros, Richard N. (15 September 2009). "Raising Your HDL Levels Increasing the GOOD cholesterol". About.com. Archived from the original on 14 July 2006. Retrieved 8 October 2009.
  33. ↑ "Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials". Ajcn.org. Archived from the original on 2012-08-14. Retrieved 2015-11-05.
  34. ↑ Ma Y, Li Y, Chiriboga DE, Olendzki BC, Hebert JR, Li W, Leung K, Hafner AR, Ockene IS (Apr 2006). "Association between carbohydrate intake and serum lipids". Journal of the American College of Nutrition. 25 (2): 155–163. doi:10.1080/07315724.2006.10719527. PMC 1479303. PMID 16582033. Archived from the original on 2012-01-15. Retrieved 2012-09-01.
  35. ↑ Siri-Tarino PW, Sun Q, Hu FB, Krauss RM (Mar 2010). "Saturated fat, carbohydrate, and cardiovascular disease". The American Journal of Clinical Nutrition. 91 (3): 502–9. doi:10.3945/ajcn.2008.26285. PMC 2824150. PMID 20089734.
  36. ↑ Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT (May 2006). "Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia". The American Journal of Clinical Nutrition. 83 (5): 1025–1031. doi:10.1093/ajcn/83.5.1025. PMID 16685042.
  37. ↑ Spate-Douglas T, Keyser RE (Jun 1999). "Exercise intensity: its effect on the high-density lipoprotein profile". Archives of Physical Medicine and Rehabilitation. 80 (6): 691–5. doi:10.1016/S0003-9993(99)90174-0. PMID 10378497.
  38. 1 2 Hausenloy DJ, Yellon DM (Jun 2008). "Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels". Heart. 94 (6): 706–14. doi:10.1136/hrt.2007.125401. PMID 18480348. S2CID 743920.
  39. ↑ Mahmassani HA, Avendano EE, Raman G, Johnson EJ (April 2018). "Avocado consumption and risk factors for heart disease: a systematic review and meta-analysis". The American Journal of Clinical Nutrition. 107 (4): 523–536. doi:10.1093/ajcn/nqx078. PMID 29635493.
  40. ↑ Rosanoff A, Seelig MS (Oct 2004). "Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals". Journal of the American College of Nutrition. 23 (5): 501S–505S. doi:10.1080/07315724.2004.10719389. PMID 15466951. S2CID 13156080. Archived from the original on 2010-08-31. Retrieved 2010-12-13. HMG CoA Reductase is an important enzyme in lipid and cholesterol metabolism, but it is not the only one. The statins act by inhibiting, temporarily, the enzyme, in a dose response relationship whereas the magnesium ion (Mg2+) is an important part of a complex control and regulation of this important pathway. Both lower LDL-C, some statins can raise HDL-C and lower triglycerides, but Mg supplements do both quite reliably.
  41. ↑ Hermansen K, Dinesen B, Hoie LH, Morgenstern E, Gruenwald J (2003). "Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: a literature review". Advances in Therapy. 20 (1): 50–78. doi:10.1007/bf02850119. PMID 12772818. S2CID 41025973.
  42. ↑ "The Power of Fish". The Cleveland Clinic Heart and Vascular Institute. Archived from the original on 17 September 2009. Retrieved 8 October 2009.
  43. ↑ "Vitamins and Supplements Lifestyle Guide – Flaxseed". WebMD. Archived from the original on 9 June 2016. Retrieved 12 August 2013.
  44. ↑ Mensink RP, Zock PL, Kester AD, Katan MB (May 2003). "Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials". The American Journal of Clinical Nutrition. 77 (5): 1146–55. doi:10.1093/ajcn/77.5.1146. PMID 12716665.
  45. ↑ "Trans fat: Avoid this cholesterol double whammy". Mayo Foundation for Medical Education and Research (MFMER). Archived from the original on 6 January 2014. Retrieved 25 June 2010.
  46. ↑ Thijssen, M. A.; Mensink, R. P. (2005). "Fatty Acids and Atherosclerotic Risk". In von Eckardstein, Arnold (ed.). Atherosclerosis: Diet and Drugs. Springer. pp. 171–172. ISBN 978-3-540-22569-0. Archived from the original on 2019-10-25.
  47. ↑ Baer DJ, Judd JT, Clevidence BA, Muesing RA, Campbell WS, Brown ED, Taylor PR (Mar 2002). "Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet". The American Journal of Clinical Nutrition. 75 (3): 593–599. doi:10.1093/ajcn/75.3.593. PMID 11864868.
  48. ↑ van der Gaag MS, van Tol A, Vermunt SH, Scheek LM, Schaafsma G, Hendriks HF (Dec 2001). "Alcohol consumption stimulates early steps in reverse cholesterol transport". Journal of Lipid Research. 42 (12): 2077–2083. doi:10.1016/S0022-2275(20)31537-6. PMID 11734581.
  49. ↑ Hendriks HF, Veenstra J, van Tol A, Groener JE, Schaafsma G (1998). "Moderate doses of alcoholic beverages with dinner and postprandial high density lipoprotein composition". Alcohol and Alcoholism. 33 (4): 403–410. doi:10.1093/oxfordjournals.alcalc.a008410. PMID 9719399.
  50. ↑ Clevidence BA, Reichman ME, Judd JT, Muesing RA, Schatzkin A, Schaefer EJ, Li Z, Jenner J, Brown CC, Sunkin M (Feb 1995). "Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study". Arteriosclerosis, Thrombosis, and Vascular Biology. 15 (2): 179–184. doi:10.1161/01.ATV.15.2.179. PMID 7749823.
  51. ↑ Cuvelier I, Steinmetz J, Mikstacki T, Siest G (May 1985). "Variations in total phospholipids and high-density lipoprotein phospholipids in plasma from a general population: reference intervals and influence of xenobiotics". Clinical Chemistry. 31 (5): 763–766. doi:10.1093/clinchem/31.5.763. PMID 3987006.
  52. ↑ Brenn T (Sep 1986). "The Tromsø heart study: alcoholic beverages and coronary risk factors". Journal of Epidemiology and Community Health. 40 (3): 249–256. doi:10.1136/jech.40.3.249. PMC 1052533. PMID 3772283.
  53. 1 2 Penner EA, Buettner H, Mittleman MA (Jul 2013). "The impact of marijuana use on glucose, insulin, and insulin resistance among US adults". The American Journal of Medicine. 126 (7): 583–9. doi:10.1016/j.amjmed.2013.03.002. PMID 23684393.
  54. ↑ Rader, Daniel J.; deGoma, Emil M. (October 2012). "Approach to the Patient with Extremely Low HDL-Cholesterol". The Journal of Clinical Endocrinology & Metabolism. 97 (10): 3399–3407. doi:10.1210/jc.2012-2185. PMC 3462950. PMID 23043194.
  55. ↑ Choi, Seul Min; Lee, Byung-Mu (2 November 2015). "Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids". Expert Opinion on Drug Safety. 14 (11): 1773–1785. doi:10.1517/14740338.2015.1094052. PMID 26401842. S2CID 8104778.
  56. ↑ Benatar JR, Stewart RA (2007). "Is it time to stop treating dyslipidaemia with fibrates?". The New Zealand Medical Journal. 120 (1261): U2706. PMID 17853928. Archived from the original on 2009-07-06. Retrieved 2009-04-29.
  57. ↑ Meyers CD, Kamanna VS, Kashyap ML (Dec 2004). "Niacin therapy in atherosclerosis". Current Opinion in Lipidology. 15 (6): 659–65. doi:10.1097/00041433-200412000-00006. PMID 15529025.
  58. ↑ Soudijn W, van Wijngaarden I, Ijzerman AP (May 2007). "Nicotinic acid receptor subtypes and their ligands". Medicinal Research Reviews. 27 (3): 417–33. doi:10.1002/med.20102. PMID 17238156. S2CID 20876888.
  59. ↑ Rader, Daniel J. (2004). "Raising HDL in Clinical Practice". Raising HDL in Clinical Practice: Clinical Strategies to Elevate HDL. Archived from the original on 12 September 2019. Retrieved 8 October 2009.
  60. 1 2 Brewer, H. Bryan (27 December 2005). "Raising HDL-Cholesterol and Reducing Cardiovascular Risk: An Expert Interview With H. Bryan Brewer, Jr, MD". Archived from the original on 12 September 2019. Retrieved 8 October 2009.
  61. ↑ Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C (Aug 2004). "Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C". Current Medical Research and Opinion. 20 (8): 1253–68. doi:10.1185/030079904125004402. PMID 15324528. S2CID 1009560.
  62. ↑ Drexel, H. (2006). "Reducing risk by raising HDL-cholesterol: the evidence". European Heart Journal Supplements. 8: F23–F29. doi:10.1093/eurheartj/sul037.
  63. ↑ Meyers CD, Carr MC, Park S, Brunzell JD (Dec 2003). "Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia". Annals of Internal Medicine. 139 (12): 996–1002. doi:10.7326/0003-4819-139-12-200312160-00009. PMID 14678919. S2CID 23980567.
  64. ↑ "Study: Boosting Good Cholesterol With Niacin Did Not Cut Heart Risks : Shots – Health News". NPR. 2011-05-26. Archived from the original on 2015-03-27. Retrieved 2015-11-05.
  65. ↑ "When is treatment indicated for high cholesterol level?". Archived from the original on 30 July 2012.
  66. ↑ Archived 1 March 2012 at the Wayback Machine
  67. ↑ Wallace JM, Schwarz M, Coward P, Houze J, Sawyer JK, Kelley KL, Chai A, Rudel LL (2005). "Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys". J Lipid Res. 46 (5): 1009–16. doi:10.1194/jlr.M500002-JLR200. PMID 15716581.
  68. ↑ Hwang JS, Ham SA, Yoo T, Lee WJ, Paek KS, Lee CH, Seo HG (2016). "Sirtuin 1 Mediates the Actions of Peroxisome Proliferator-Activated Receptor δ on the Oxidized Low-Density Lipoprotein-Triggered Migration and Proliferation of Vascular Smooth Muscle Cells". Mol Pharmacol. 90 (5): 522–529. doi:10.1124/mol.116.104679. PMID 27573670.
  69. ↑ Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ (2009). PS 895 - Rat carcinogenicity study with GW501516, a PPAR delta agonist (PDF). 48th Annual Meeting of the Society of Toxicology. Baltimore: Society of Toxicology. p. 105. Archived from the original (PDF) on 2015-05-04.
  70. ↑ Newsholme SJ, Dunsford WS, Brodie T, Brennan C, Brown M, Geiger LE (2009). PS 896 - Mouse carcinogenicity study with GW501516, a PPAR delta agonist (PDF). 48th Annual Meeting of the Society of Toxicology. Baltimore: Society of Toxicology. p. 105. Archived from the original (PDF) on 2015-05-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.